FRI0600 THE EFFICACY OF DIFFERENT COLCHICINE DOSES IN TREATMENT OF FAMILIAL MEDITERRANEAN FEVER PATIENTS
E. Uguztemur, S. Çelik, S. Sadri, E. Aşçı, G. Ergun, Ö. Velipaşalar, S. Yılmaz-Öner, C. Bes, N. Alpay-Kanıtez. Bakırköy Dr.Sadi Konuk Research and Training Hospital, Istanbul, Turkey Background: Recommended colchicine dose in familial mediterranean fever (FMF) is 1-1.5 mg/day in adults. If necessary it can be increased up to 3 mg/day by clinical monitoring. In the final FMF recommendation report of the EULAR, it was reported that after 5 years of stable disease, in appropriate patients, the dose of colchicine may be reduced by close follow-up. However, the number of clinical trials supporting this recommendation is not enough. Objectives: In this study, demographic and clinical characteristics of FMF patients whose disease under control and treated with different doses of colchicine were compared. Methods: Among the all FMF patients attending to the rheumatology outpatient clinic between April and September 2016, only the patients in non-attacks period at least for the last 1 month were included to the study. Clinical and laboratory findings, MEFV gene mutations, drug compliance of the patients and duration and doses of the colchicine treatment were recorded. The 'international severity scoring system for familial mediterranean fever' (ISSF) score was calculated to determine disease severity. The patients who were under the control (less than 4 attacks per year and ISSF score ≤2) divided to three gruops. These gruops were the patients taking low dose (average daily dose of colchicin <1 mg), median dose>1 mg/day and<1.5 mg/ day and standard dose ≥1.5 mg/colchicine treatment at least for 3 years. Patients treated with DMARDs or biological therapy were excluded from the study. Results: Of the 162 FMF patients enrolled into the ongoing cohort, 86 patients were excluded from the study due to 57 patients had active disease, 19 had not yet completed 3 years of colchicine treatment and 10 patients received biological or DMARD treatment. The remaining 76 patients (25 male, 51 female) met the study criteria. The mean age was 32±11.5 years and the disease duration was 18.2±10.9 years. Amyloidosis or organ failure was not detected in any of these patients. Because of various reasons (drug side effect, treatment incompatibility, physician advice), 16 patients (21%) were treated with low dose colchicine (group A), 30 patients (39%) with moderate dose of colchicine (group B) and the remaining 30 patients (39%) with standard dose colchicine (group C). There were no statistically significant differences in demographic, clinical or laboratory data among these 3 subgroups.
Conclusions: Disease control in FMF is important to prevent amyloidosis and improve the quality of life. Recent studies contribute to the determination of treatment goals. Reducing the colchicine dose may increase drug compliance in this lifelong treatment. In our study, there was no difference between the treatment groups in amyloidosis, MEFV gene mutation or subclinical inflammation. These findings suggest that the dose of colchicine maybe reduced in inactive patients who determineted by the number of annual episodes and the ISSF score. Background: Hyperferritinemia is associated with severe inflammatory conditions, such as rheumatic diseases with systemic inflammatory responses, and multiorgan dysfunction syndromes. Objectives: To determine which diseases are associated with hyperferritinemia in a tertiary hospital; to compare ferritin levels between these different entities and to evaluate relationship between levels of ferritin and mortality in these patients. Methods: A retrospective study was carried out in which all patients over 18 years with at least one determination of serum ferritin equal to or greater than 1000 ng/ml were identified in the laboratory database of our hospital between 1/1/2006 and 6/30/2016. Corresponding electronic medical records were reviewed and demographic data and clinical data were collected. Mortality was assessed at the end of follow-up. Descriptive statistical analysis and logistic regression analysis were performed in order to identify variables associated with mortality. Results: A total of 1979 patients were included, 1235 men (62.4%) with a mean age of 63.2 years (SD 17.2). Only 36 patients (1.8%) presented a rheumatologic diagnosis as the only cause of high levels of ferritin, with Still's disease (n=8) and systemic Vasculitis (n=9) being the main diagnoses. Table 1 shows patients' characteristics grouped according to whether the elevation of ferritin was associated with a rheumatic disease or not. Median serum ferritin and transferrin saturation in both groups were similar (see Table 1 ). Mortality was lower for rheumatologic causes (5.9% vs 37.2%, p<0.001). Variables that were associated with mortality in multivariable logistic regression analysis were: maximum ferritin value (OR 1,0004, 95% CI 1,0003-1,0004, p<0.001) and age (OR 1.03, 95% CI 1.02-1.04, p<0.001), whereas the diagnosis of a rheumatic disease was a protective factor (OR 0.11, 95% CI 0.03-0.47, p=0.003). ROC curve for ferritin and mortality showed an area under the curve of 0.59 (95% CI 0.58-0.62). Ferritin levels greater than 3000 ng/ml showed a specificity of 89.2% and a sensitivity of 19.7% for mortality, regardless of cause of ferritin elevation. Conclusions: Rheumatic diseases, represents a very small percentage of the causes of elevation of ferritin above 1000 ng/ml, and were associated with lower mortality than the non-rheumatic causes. Serum ferritin levels were significantly associated with increased mortality regardless of the underlying cause. 
